ICON plc Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



ICON Awarded Best CRO at World Vaccine Congress 2017

ICON recognised for continually setting standards of excellence in vaccine development

DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded Best Clinical Research Organisation at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place in Washington this week.

The ViE Awards honour individuals and organisations that continually set standards of excellence and have made outstanding achievements in the vaccine industry over the past 12 months. ICON was selected by a panel of senior industry representatives from government, academia, pharmaceutical and biotech organisations as the best CRO according to the following criteria:

"We are very proud to be recognised as the world's best CRO in vaccine development," commented Dr. Steve Cutler, Chief Executive Officer, ICON plc. "Over the past year, we have expanded the capabilities of our Vaccine Centre of Excellence to provide commercial and government clients with the services, site relationships and geographic footprint they need to develop vaccines for a wide range of infectious diseases and global viral epidemics. This award is recognition of the hard work and dedication of the ICON vaccines team and I'm delighted to see their efforts being honoured as the industry's best."

ICON's Vaccine Centre of Excellence combines in-depth vaccine experience, extensive laboratory testing, enabling technologies and longstanding site partnerships to help commercial and government clients take time and cost from their vaccine development programmes. In 2016, ICON acquired ClinicalRM, which enhanced ICON's capabilities in infectious diseases, vaccine development and the response to bio-threats and global viral epidemics. ICON's vaccine site relationships in over 40 countries offers clients accelerated vaccine patient recruitment capabilities, which were further enhanced in 2015 through the acquisition of PMG Research, an owned network of clinical research sites in 14 metropolitan areas in the US.

Learn more about ICON's vaccines experience at www.iconplc.com/vaccines

About ICON plc

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 87 locations in 38 countries and has approximately 12,500 employees. Further information is available at www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON/ICLR-G

ICON Media Contact
Weber Shandwick
Camille Frederix
Tel: +44 (0)207 067 0272
Email: cfrederix@webershandwick.com

Source: ICON

News Provided by Acquire Media

Close window | Back to top